Phase 3 Ovarian Cancer Trial, Recruiting NCT06817161 Sponsor: Centre Francois Baclesse Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT06817161
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You are generally able to carry out daily activities, with little to no limitation from your health condition (confirm with trial site)
  • Your cancer has been confirmed by a laboratory test to be epithelial ovarian carcinoma (a specific type of ovarian cancer)
  • Your cancer is at an advanced enough stage (FIGO stage IIB or higher) (confirm with trial site)
  • You are due to start your first course of chemotherapy, whether before or after surgery, or on its own
  • You are covered by an appropriate social security or health insurance system
  • You are willing and able to sign a consent form before taking part in any trial activities

Who may not be able to join:

  • You have an active implanted medical device such as a pacemaker or defibrillator
  • You have skin problems in the area where the stimulation patches or electrodes would be placed
  • You have had epileptic seizures within the last 2 years
  • You have a serious heart or cardiovascular condition, or a heart rhythm problem that cannot be controlled (confirm with trial site)
  • You have a serious ear condition
  • You have a confirmed nerve condition affecting your automatic bodily functions (confirm with trial site)
  • The shape of your left ear makes it impossible to use the trial device
  • You have a cochlear implant close to where the device would be used
  • You have significant difficulties with memory or thinking
  • You have another active cancer, unless it is a treated skin cancer (non-melanoma) or a treated early-stage cervical cancer
  • You are pregnant or breastfeeding
  • You are already taking part in another clinical trial that could interfere with this one
  • The trial team feels you may be unable or unwilling to follow the trial requirements
  • You are legally under the guardianship of another person or have restrictions on your freedom

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0231455050

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Centre Francois Baclesse
Registry
ClinicalTrials.gov
Start date
30 April 2025
Est. completion
30 June 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

assess the impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared t

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov